



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, D.C. 20231  
 www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/085,233	02/28/2002	Maria Alexandra Glucksman	MP101-021P1RNM

Jean M. Silveri  
 Millennium Pharmaceuticals, Inc.  
 75 Sidney Street  
 Cambridge, MA 02139



CONFIRMATION NO. 6932

## FORMALITIES LETTER



\*OC000000008567084\*

Date Mailed: 08/02/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
 DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*of the us*  


---

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



0350

Actioner's Docket No. MPI01-021P1RNM**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: **Maria Alexandra Glucksmann**  
Application No.: **10/085,233** Group No.: **1645**  
Filed: **February 28, 2002** Examiner: **N/A**  
For: **93870, A HUMAN G-PROTEIN COUPLED RECEPTOR AND USES THEREFOR**

**Box Sequence**  
**Commissioner for Patents**  
**P.O. Box 2327**  
**Arlington, VA 22202**

**SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY,  
AND/OR AMENDMENT PERTAINING THERETO  
FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE  
AND/OR AMINO ACID SEQUENCE**

1.  This replies to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated August 2, 2002.
- A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures is enclosed.

**IDENTIFICATION OF PERSON MAKING STATEMENT**2. I, Jean M. Silveri*(type or print name of person signing below)*

state the following:

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Box Sequence, P.O. Box 2327, Arlington, VA 22202.  
**37 C.F.R. SECTION 1.8(a)** **37 C.F.R. SECTION 1.10\***

with sufficient postage as first class mail.

as "Express Mail Post Office to Address"  
Mailing Label No. \_\_\_\_\_

**TRANSMISSION**

transmitted by facsimile to the Patent and Trademark Office.

  
**Signature****Simonne Corriveau***(type or print name of person certifying)*Date: September 30, 2000

**\*WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**ITEMS BEING SUBMITTED**

3. Submitted herewith is/are:

- A.  7 pages of "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. Section 1.821(c) and 37 C.F.R. Sections 1.822 and 1.823.
- B.  An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. Section 1.821(d).
- C.  A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. Sections 1.821(e) and 1.824.
- D.  Please transfer to this application, in accordance with 37 C.F.R. Section 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

In re application of:

Application No.:

Group No.:

Filed:

Examiner:

For:

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form

"Sequence Identifier"

(other application)

(this application)

- E.  A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. Section 1.821(g).
  - Because the statement is not made by a person registered to practice before the Office, the Statement is verified as required in 37 C.F.R. Section 1.821(b).

**Practitioner's Docket No. MPI01-021P1RNM**

F.  Because this submission is made in fulfilling the requirement under 37 C.F.R. Section 1.821(g), a statement that the submission includes no new matter.

Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. Section 1.821(g).

**STATEMENT THAT "SEQUENCE LISTING"  
AND COMPUTER READABLE COPY ARE THE SAME  
AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER**

4. I hereby state:

A.  Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.

B.  All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

**EXTENSION OF TERM**

5. The proceedings herein are for a patent application and the provisions of 37 C.F.R. Section 1.136 apply.

(a)  Applicant petitions for an extension of time under 37 C.F.R. Section 1.136 (fees: 37 C.F.R. Section 1.17(a)(1)-(4)) for the total number of months checked below:

<u>Extension (months)</u>	<u>Fee for other than small entity</u>	<u>Fee for small entity</u>
<input type="checkbox"/> one month	\$ 110.00	\$ 55.00
<input type="checkbox"/> two months	\$ 390.00	\$ 195.00
<input type="checkbox"/> three months	\$ 890.00	\$ 445.00
<input type="checkbox"/> four months	\$1,390.00	\$ 695.00
		<b>Fee    \$0.00</b>

If an additional extension of time is required, please consider this a petition therefor.

An extension for        months has already been secured, and the fee paid therefor of  
\$0.00 is deducted from the total fee due for the total months of extension  
now requested.

Extension fee due with this request \$0.00

Practitioner's Docket No. **MPI01-021P1RNM**

**OR**

(b)  Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

**FEE PAYMENT**

6.  Attached is a check in the sum of \$\_\_\_\_\_.

Charge Account No. 501668 the sum of \$0.00.  
A duplicate of this transmittal is attached.


**FEE DEFICIENCY**

8.  If any additional extension and/or fee is required, charge Account No. 501668.

September 30, 2002

**MILLENNIUM PHARMACEUTICALS, INC.**

By



Jean M. Silveri  
Registration No. 39,030  
75 Sidney Street  
Cambridge, MA 02139  
Telephone - 617-679-7336  
Facsimile - 617-551-8820



BIOTECH  
SYSTEMS  
BRANCH

05/0  
06/0

## RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/085,233A  
Source: OIPE  
Date Processed by STIC: 6/17/02

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: [patin3help@uspto.gov](mailto:patin3help@uspto.gov) or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>), EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:  
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202  
Or  
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002



O I P E

Does Not Comply  
Corrected Diskette Needed See pg. 7

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/10/085,233A

DATE: 06/17/2002  
TIME: 14:46:04

Input Set : A:\pto.vsk.txt  
Output Set: N:\CRF3\06172002\J085233A.raw

for explanation of  
errors

3 <110> APPLICANT: YISSUM Research Development Company of the Hebrew University of Jerusalem

5 <120> TITLE OF INVENTION: Fcε-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES, A

6 METHOD FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME  
8 <130> FILE REFERENCE: 1268-067

C--> 10 <140> CURRENT APPLICATION NUMBER: US/10/085,233A

C--> 11 <141> CURRENT FILING DATE: 2002-06-10

13 <150> PRIOR APPLICATION NUMBER: IL 116436

14 <151> PRIOR FILING DATE: 1995-12-18

16 <150> PRIOR APPLICATION NUMBER: PCT / IL96 / 00181

17 <151> PRIOR FILING DATE: 1996-12-18

19 <160> NUMBER OF SEQ ID NOS: 8

21 <170> SOFTWARE: PatentIn version 3.0

23 <210> SEQ ID NO: 1

24 <211> LENGTH: 1512

25 <212> TYPE: DNA

C--> 26 <213> ORGANISM: Artificial

28 <220> FEATURE:

29 <223> OTHER INFORMATION: Description of Artificial Sequence: Fcε2-3-PE40

31 <220> FEATURE:

32 <221> NAME/KEY: CDS

33 <222> LOCATION: (1)..(1512)

35 <400> SEQUENCE: 1

36 atg gag cag caa tgg atg tct gaa agc acc ttc acc tgc aag gtc acc 48  
37 Met Glu Gln Gln Trp Met Ser Glu Ser Thr Phe Thr Cys Lys Val Thr

38 1 5 10 15

40 tcc caa ggc gta gac tat ttg gcc cac act cgg aga tgc cca gat cat 96  
41 Ser Gln Gly Val Asp Tyr Leu Ala His Thr Arg Arg Cys Pro Asp His

42 20 25 30

44 gag cca gcc ggt gtg att acc tac ctg atc cca ccc agc ccc ctg gac 144  
45 Glu Pro Ala Gly Val Ile Thr Tyr Leu Ile Pro Pro Ser Pro Leu Asp

46 35 40 45

48 ctg tat caa aac ggt gct ccc aag ctt acc tgt ctg gtg gac ctg 192  
49 Leu Tyr Gln Asn Gly Ala Pro Lys Leu Thr Cys Leu Val Val Asp Leu

50 50 55 60

52 gaa agc gag aag aat gtc aat gtg acg tgg aac caa gag aag aag act 240  
53 Glu Ser Glu Lys Asn Val Asn Val Thr Trp Asn Gln Glu Lys Lys Thr

54 65 70 75 80

56 tca gtc tca gca tcc cag tgg tac act aag cac cac aat aac gcc aca 288  
57 Ser Val Ser Ala Ser Gln Trp Tyr Thr Lys His His Asn Asn Ala Thr

58 85 90 95

60 act agt atc acc tcc atc ctg cct gta gtt gcc aag gac tgg att gaa 336  
61 Thr Ser Ile Thr Ser Ile Leu Pro Val Val Ala Lys Asp Trp Ile Glu

62

100

105

110

6/17/02

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/10/085,233A

DATE: 06/17/2002  
TIME: 14:46:04

Input Set : A:\pto.vsk.txt  
Output Set: N:\CRF3\06172002\J085233A.raw

64 ggc tac ggc tat cag tgc ata gtg gac cac cct gat ttt ccc aag ccc	384
65 Gly Tyr Gly Tyr Gln Cys Ile Val Asp His Pro Asp Phe Pro Lys Pro	
66 115 120 125	
68 att gtg cgt tcc atc acc aag acc cca cat atg gcc gaa gag ggc ggc	432
69 Ile Val Arg Ser Ile Thr Lys Thr Pro His Met Ala Glu Glu Gly Gly	
70 130 135 140	
72 agc ctg gcc ggc ctg acc gcg cac cag gct tgc cac ctg ccg ctg gag	480
73 Ser Leu Ala Ala Leu Thr Ala His Gln Ala Cys His Leu Pro Leu Glu	
74 145 150 155 160	
76 act ttc acc cgt cat cgc cag ccg cgc ggc tgg gaa caa ctg gag cag	528
77 Thr Phe Thr Arg His Arg Gln Pro Arg Gly Trp Glu Gln Leu Glu Gln	
78 165 170 175	
80 tgc ggc tat ccg gtg cag egg ctg gtc gcc ctc tac ctg gcg gcg cgg	576
81 Cys Gly Tyr Pro Val Gln Arg Leu Val Ala Leu Tyr Leu Ala Ala Arg	
82 180 185 190	
84 ctg tcg tgg aac cag gtc gac cag gtg atc cgc aac gcc ctg gcc agc	624
85 Leu Ser Trp Asn Gln Val Asp Gln Val Ile Arg Asn Ala Leu Ala Ser	
86 195 200 205	
88 ccc ggc agc ggc ggc gac ctg ggc gaa gcg atc cgc gag cag ccg gag	672
89 Pro Gly Ser Gly Gly Asp Leu Gly Glu Ala Ile Arg Glu Gln Pro Glu	
90 210 215 220	
92 cag gcc cgt ctg gcc ctg acc ctg gcc ggc gag agc gag cgc ttc	720
93 Gln Ala Arg Leu Ala Leu Thr Leu Ala Ala Glu Ser Glu Arg Phe	
94 225 230 235 240	
96 gtc cgg cag ggc acc ggc aac gac gag gcc ggc gcg gcc aac gcc gac	768
97 Val Arg Gln Gly Thr Gly Asn Asp Glu Ala Gly Ala Ala Asn Ala Asp	
98 245 250 255	
100 gtg gtg agc ctg acc tgc ccg gtc gcc ggc ggt gaa tgc gcg ggc ccc	816
101 Val Val Ser Leu Thr Cys Pro Val Ala Ala Gly Glu Cys Ala Gly Pro	
102 260 265 270	
104 gcg gac agc ggc gac gcc ctg ctg gag cgc aac tat ccc act ggc gcg	864
105 Ala Asp Ser Gly Asp Ala Leu Leu Glu Arg Asn Tyr Pro Thr Gly Ala	
106 275 280 285	
108 gag ttc ctc ggc gac ggc gac gtc agc ttc agc acc cgc ggc acg	912
109 Glu Phe Leu Gly Asp Gly Gly Asp Val Ser Phe Ser Thr Arg Gly Thr	
110 290 295 300	
112 cag aac tgg acg gtg gag cgg ctg ctc cag gcg cac cgc caa ctg gag	960
113 Gln Asn Trp Thr Val Glu Arg Leu Leu Gln Ala His Arg Gln Leu Glu	
114 305 310 315 320	
116 gag cgc ggc tat gtg ttc gtc ggc tac cac ggc acc ttc ctc gaa gcg	1008
117 Glu Arg Gly Tyr Val Phe Val Gly Tyr His Gly Thr Phe Leu Glu Ala	
118 325 330 335	
120 gcg caa agc atc gtc ttc ggc ggg gtg cgc gcg cgc agc cag gac ctc	1056
121 Ala Gln Ser Ile Val Phe Gly Gly Val Arg Ala Arg Ser Gln Asp Leu	
122 340 345 350	
124 gac gcg atc tgg cgc ggt ttc tat atc gcc ggc gat ccg gcg ctg gcc	1104
125 Asp Ala Ile Trp Arg Gly Phe Tyr Ile Ala Gly Asp Pro Ala Leu Ala	
126 355 360 365	
128 tac ggc tac gcc cag gac cag gaa ccc gac gca cgc ggc cgg atc cgc	1152

RAW SEQUENCE LISTING DATE: 06/17/2002  
PATENT APPLICATION: US/10/085,233A TIME: 14:46:04

Input Set : A:\pto.vsk.txt  
Output Set: N:\CRF3\06172002\J085233A.raw

129 Tyr Gly Tyr Ala Gln Asp Gln Glu Pro Asp Ala Arg Gly Arg Ile Arg  
 130 370 375 380  
 132 aac ggt gcc ctg ctg cgg gtc tat gtc ccg cgc tcg agc ctg ccg ggc 1200  
 133 Asn Gly Ala Leu Leu Arg Val Tyr Val Pro Arg Ser Ser Leu Pro Gly  
 134 385 390 395 400  
 136 ttc tac cgc acc agc ctg acc ctg gcc gcg ccg gag gcg ggc ggc gag 1248  
 137 Phe Tyr Arg Thr Ser Leu Thr Leu Ala Ala Pro Glu Ala Ala Gly Glu  
 138 405 410 415  
 140 gtc gaa cgg ctg atc ggc cat ccg ctg ccg cgc ctg gac gcc atc 1296  
 141 Val Glu Arg Leu Ile Gly His Pro Leu Pro Leu Arg Leu Asp Ala Ile  
 142 420 425 430  
 144 acc ggc ccc gag gag gaa ggc ggg cgc ctg gag acc att ctc ggc tgg 1344  
 145 Thr Gly Pro Glu Glu Gly Gly Arg Leu Glu Thr Ile Leu Gly Trp  
 146 435 440 445  
 148 ccg ctg gcc gag cgc acc gtg gtg att ccc tcg gcg atc ccc acc gac 1392  
 149 Pro Leu Ala Glu Arg Thr Val Val Ile Pro Ser Ala Ile Pro Thr Asp  
 150 450 455 460  
 152 ccg cgc aac gtc ggc ggc gac ctc gac ccg tcc agc atc ccc gac aag 1440  
 153 Pro Arg Asn Val Gly Gly Asp Leu Asp Pro Ser Ser Ile Pro Asp Lys  
 154 465 470 475 480  
 156 gaa cag gcg atc agc gcc ctg ccg gac tac gcc agc cag ccc ggc aaa 1488  
 157 Glu Gln Ala Ile Ser Ala Leu Pro Asp Tyr Ala Ser Gln Pro Gly Lys  
 158 485 490 495  
 160 ccg ccg cgc gag gac ctg aag taa 1512  
 161 Pro Pro Arg Glu Asp Leu Lys  
 162 500  
 165 <210> SEQ ID NO: 2  
 166 <211> LENGTH: 503  
 167 <212> TYPE: PRT  
 168 <213> ORGANISM: Artificial  
 170 <220> FEATURE:  
 170 <223> OTHER INFORMATION:  
 170 <400> SEQUENCE: 2  
 172 Met Glu Gln Gln Trp Met Ser Glu Ser Thr Phe Thr Cys Lys Val Thr  
 173 1 5 10 15  
 176 Ser Gln Gly Val Asp Tyr Leu Ala His Thr Arg Arg Cys Pro Asp His  
 177 20 25 30  
 180 Glu Pro Ala Gly Val Ile Thr Tyr Leu Ile Pro Pro Ser Pro Leu Asp  
 181 35 40 45  
 184 Leu Tyr Gln Asn Gly Ala Pro Lys Leu Thr Cys Leu Val Val Asp Leu  
 185 50 55 60  
 188 Glu Ser Glu Lys Asn Val Asn Val Thr Trp Asn Gln Glu Lys Lys Thr  
 189 65 70 75 80  
 192 Ser Val Ser Ala Ser Gln Trp Tyr Thr Lys His His Asn Asn Ala Thr  
 193 85 90 95  
 196 Thr Ser Ile Thr Ser Ile Leu Pro Val Val Ala Lys Asp Trp Ile Glu  
 197 100 105 110  
 200 Gly Tyr Gly Tyr Gln Cys Ile Val Asp His Pro Asp Phe Pro Lys Pro  
 201 115 120 125

file:///C:/CRF3/Outhold/VsrJ085233A.htm

6/17/02

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/10/085,233A

DATE: 06/17/2002  
TIME: 14:46:04

Input Set : A:\pto.vsk.txt  
Output Set: N:\CRF3\06172002\J085233A.raw

204 Ile Val Arg Ser Ile Thr Lys Thr Pro His Met Ala Glu Glu Gly Gly  
205 130 135 140  
208 Ser Leu Ala Ala Leu Thr Ala His Gln Ala Cys His Leu Pro Leu Glu  
209 145 150 155 160  
212 Thr Phe Thr Arg His Arg Gln Pro Arg Gly Trp Glu Gln Leu Glu Gln  
213 165 170 175  
216 Cys Gly Tyr Pro Val Gln Arg Leu Val Ala Leu Tyr Leu Ala Ala Arg  
217 180 185 190  
220 Leu Ser Trp Asn Gln Val Asp Gln Val Ile Arg Asn Ala Leu Ala Ser  
221 195 200 205  
224 Pro Gly Ser Gly Gly Asp Leu Gly Glu Ala Ile Arg Glu Gln Pro Glu  
225 210 215 220  
228 Gln Ala Arg Leu Ala Leu Thr Leu Ala Ala Glu Ser Glu Arg Phe  
229 225 230 235 240  
232 Val Arg Gln Gly Thr Gly Asn Asp Glu Ala Gly Ala Ala Asn Ala Asp  
233 245 250 255  
236 Val Val Ser Leu Thr Cys Pro Val Ala Ala Gly Glu Cys Ala Gly Pro  
237 260 265 270  
240 Ala Asp Ser Gly Asp Ala Leu Leu Glu Arg Asn Tyr Pro Thr Gly Ala  
241 275 280 285  
244 Glu Phe Leu Gly Asp Gly Gly Asp Val Ser Phe Ser Thr Arg Gly Thr  
245 290 295 300  
248 Gln Asn Trp Thr Val Glu Arg Leu Leu Gln Ala His Arg Gln Leu Glu  
249 305 310 315 320  
252 Glu Arg Gly Tyr Val Phe Val Gly Tyr His Gly Thr Phe Leu Glu Ala  
253 325 330 335  
256 Ala Gln Ser Ile Val Phe Gly Gly Val Arg Ala Arg Ser Gln Asp Leu  
257 340 345 350  
260 Asp Ala Ile Trp Arg Gly Phe Tyr Ile Ala Gly Asp Pro Ala Leu Ala  
261 355 360 365  
264 Tyr Gly Tyr Ala Gln Asp Gln Glu Pro Asp Ala Arg Gly Arg Ile Arg  
265 370 375 380  
268 Asn Gly Ala Leu Leu Arg Val Tyr Val Pro Arg Ser Ser Leu Pro Gly  
269 385 390 395 400  
272 Phe Tyr Arg Thr Ser Leu Thr Leu Ala Ala Pro Glu Ala Ala Gly Glu  
273 405 410 415  
276 Val Glu Arg Leu Ile Gly His Pro Leu Pro Leu Arg Leu Asp Ala Ile  
277 420 425 430  
280 Thr Gly Pro Glu Glu Glu Gly Gly Arg Leu Glu Thr Ile Leu Gly Trp  
281 435 440 445  
284 Pro Leu Ala Glu Arg Thr Val Val Ile Pro Ser Ala Ile Pro Thr Asp  
285 450 455 460  
288 Pro Arg Asn Val Gly Gly Asp Leu Asp Pro Ser Ser Ile Pro Asp Lys  
289 465 470 475 480  
292 Glu Gln Ala Ile Ser Ala Leu Pro Asp Tyr Ala Ser Gln Pro Gly Lys  
293 485 490 495  
296 Pro Pro Arg Glu Asp Leu Lys  
297 500  
300 <210> SEQ ID NO: 3

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/10/085,233A

DATE: 06/17/2002  
TIME: 14:46:04

Input Set : A:\pto.vsk.txt  
Output Set: N:\CRF3\06172002\J085233A.raw

301 <211> LENGTH: 2031  
302 <212> TYPE: DNA  
C--> 303 <213> ORGANISM: Artificial  
305 <220> FEATURE:  
306 <223> OTHER INFORMATION: Description of Artificial Sequence: Fce2-4-PE40  
308 <220> FEATURE:  
309 <221> NAME/KEY: CDS  
310 <222> LOCATION: (1)..(2031)  
312 <400> SEQUENCE: 3  
313 atg cga cct gtc aac atc act gag ccc acc ttg gag cta ctc cat tca 48  
314 Met Arg Pro Val Asn Ile Thr Glu Pro Thr Leu Glu Leu Leu His Ser  
315 1 5 10 15  
317 tcc tgc gac ccc aat gca ttc cac tcc acc atc cag ctg tac tgc ttc 96  
318 Ser Cys Asp Pro Asn Ala Phe His Ser Thr Ile Gln Leu Tyr Cys Phe  
319 20 25 30  
321 att tat ggc cac atc cta aat gat gtc tct gtc agc tgg cta atg gac 144  
322 Ile Tyr Gly His Ile Leu Asn Asp Val Ser Val Ser Trp Leu Met Asp  
323 35 40 45  
325 gat cgg gag ata act gat aca ctt gca caa act gtt cta atc aag gag 192  
326 Asp Arg Glu Ile Thr Asp Thr Leu Ala Gln Thr Val Leu Ile Lys Glu  
327 50 55 60  
329 gaa ggc aaa cta gcc tot acc tgc agt aaa ctc aac atc act gag cag 240  
330 Glu Gly Lys Leu Ala Ser Thr Cys Ser Lys Leu Asn Ile Thr Glu Gln  
331 65 70 75 80  
333 caa tgg atg tct gaa agc acc ttc acc tgc aag gtc acc tcc caa ggc 288  
334 Gln Trp Met Ser Glu Ser Thr Phe Thr Cys Lys Val Thr Ser Gln Gly  
335 85 90 95  
337 gta gac tat ttg gcc cac act cgg aga tgc cca gat cat gag cca cgg 336  
338 Val Asp Tyr Leu Ala His Thr Arg Arg Cys Pro Asp His Glu Pro Arg  
339 100 105 110  
341 ggt gtg att acc tac ctg atc cca ccc agc ccc ctg gac ctg tat caa 384  
342 Gly Val Ile Thr Tyr Leu Ile Pro Pro Ser Pro Leu Asp Leu Tyr Gln  
343 115 120 125  
345 aac ggt gct ccc aag ctt acc tgt ctg gtg gac ctg gaa agc gag 432  
346 Asn Gly Ala Pro Lys Leu Thr Cys Leu Val Val Asp Leu Glu Ser Glu  
347 130 135 140  
349 aag aat gtc aat gtg acg tgg aac caa gag aag aag act tca gtc tca 480  
350 Lys Asn Val Asn Val Thr Trp Asn Gln Glu Lys Lys Thr Ser Val Ser  
351 145 150 155 160  
353 gca tcc cag tgg tac act aag cac cac aat aac ggc aca act agt atc 528  
354 Ala Ser Gln Trp Tyr Thr Lys His His Asn Asn Gly Thr Thr Ser Ile  
355 165 170 175  
357 acc tcc atc ctg cct gta gtt gcc aag gac tgg att gaa ggc tac ggc 576  
358 Thr Ser Ile Leu Pro Val Val Ala Lys Asp Trp Ile Glu Gly Tyr Gly  
359 180 185 190  
361 tat cag tgc ata gtg gac cac cct gat ttt ccc aag ccc att gtg cgt 624  
362 Tyr Gln Cys Ile Val Asp His Pro Asp Phe Pro Lys Pro Ile Val Arg  
363 195 200 205  
365 tcc atc acc aag acc cca ggc cag cgc tca gcc ccc gag gta tat gtg 672

RAW SEQUENCE LISTING ERROR SUMMARY  
PATENT APPLICATION: US/10/085,233A

DATE: 06/17/2002  
TIME: 14:46:05

Input Set : A:\pto.vsk.txt  
Output Set: N:\CRF3\06172002\J085233A.raw

Invalid Line Length:

The rules require that a line not exceed 72 characters in length. This includes spaces.

Seq#:1; Line(s) 3

Invalid <213> Response:

Use of "Artificial" only as "<213> Organism" response is incomplete,  
per 1.823(b) of New Sequence Rules. Valid response is Artificial Sequence.

Seq#:1,2,3,4

Use of <220> Feature(NEW RULES):

Sequence(s) are missing the <220> Feature and associated headings.

Use of <220> to <223> is MANDATORY if <213> ORGANISM is "Artificial Sequence"  
or "Unknown". Please explain source of genetic material in <220> to <223>  
section (See "Federal Register," 6/01/98, Vol. 63, No. 104, pp.29631-32)  
(Sec.1.823 of new Rules)

Seq#:2,4

VERIFICATION SUMMARY  
PATENT APPLICATION: US/10/085,233A

DATE: 06/17/2002  
TIME: 14:46:05

Input Set : A:\pto.vsk.txt  
Output Set: N:\CRF3\06172002\J085233A.raw

L:10 M:270 C: Current Application Number differs, Replaced Current Application Number  
L:11 M:271 C: Current Filing Date differs, Replaced Current Filing Date  
L:26 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:1  
L:168 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:2  
L:170 M:258 W: Mandatory Feature missing, <220> FEATURE:  
L:170 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:  
L:303 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:3  
L:489 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:4  
L:491 M:258 W: Mandatory Feature missing, <220> FEATURE:  
L:491 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION: